Form 4: Edwards Lifesciences CFO Scott Ullem Reports Stock Transactions

Scott Ullem, CFO of Edwards Lifesciences, reports the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan.

Summary

• On June 20, 2024, Scott Ullem, the Chief Financial Officer of Edwards Lifesciences, executed transactions involving the company's common stock.
• Ullem exercised employee stock options to acquire 5,625 shares at a price of $45.2767 per share.
• Simultaneously, Ullem sold 400 shares at a weighted average price of $88.1125 and 5,225 shares at a weighted average price of $87.4666.
• Following these transactions, Ullem directly owns 30,561 shares of common stock and indirectly owns 266,318 shares through a trust.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider trading activity.
• The stock sales may have a minor impact on the stock price, depending on market conditions and investor sentiment.

Key Dates